Use of the amniotic fluid stem cell selectome in the treatment of dry eye disease

The use of amniotic fluid stem cell secretome addresses the inefficacy of current treatments for dry eye disease and corneal wounds by improving tear secretion and promoting wound healing through topical administration.

JP7580130B2Active Publication Date: 2024-11-11U NEURON BIOMEDICAL INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022088361
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-06-01
Filing Date
2022-05-31
Publication Date
2024-11-11
Estimated Expiration
2042-05-31

AI Technical Summary

Technical Problem

Current treatments for dry eye disease and corneal wounds are often time-consuming, frustrating, and ineffective, necessitating the development of new therapeutic agents.

Method used

Administering a composition comprising an amniotic fluid stem cell secretome, obtained by culturing amniotic fluid stem cells in a basal medium, centrifuging, and filtering the supernatant, which can be used topically in the form of eye drops, gels, or ointments.

Benefits of technology

The amniotic fluid stem cell secretome effectively alleviates dry eye symptoms and promotes corneal epithelial wound healing by improving tear secretion, reducing inflammation, and enhancing cell proliferation and migration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580130000004
    Figure 0007580130000004
  • Figure 0007580130000005
    Figure 0007580130000005
  • Figure 0007580130000006
    Figure 0007580130000006
Patent Text Reader

Abstract

To provide a novel therapeutic drug of dry eye disease which can effectively alleviate symptoms.SOLUTION: A pharmaceutical composition to be used for treatment of dry eye disease or treatment of cornea wound includes secretome of an amniotic fluid stem cell, where secretome is prepared by a method including the following processes of: culturing an amniotic fluid stem cell on a basal medium for 24 to 72 hours to obtain a conditioned medium; recovering culture medium supernatant after centrifugal separation; and filtering the supernatant to obtain secretome.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to the use of amniotic fluid stem cell secretomes in the treatment of dry eye disease and in the treatment of corneal wounds. [Background technology]

[0002] Amniotic fluid cells are used as a routine prenatal diagnostic to detect whether the fetus has chromosomal abnormalities. It has also been found that small nucleated cells with characteristics of hematopoietic progenitor cells can be identified in amniotic fluid before 12 weeks of gestation, suggesting that these cells may be derived from the yolk sac. From 2004 to 2006, several reports were published that successfully isolated and identified the presence of another group of stem cells in amniotic fluid. These amniotic fluid stem cells have been proven to express certain biomarkers of both mesenchymal stem cells and neural stem cells, and have the ability to differentiate into bone, cartilage, fat, and neural cells. It has been confirmed that amniotic fluid stem cells can be stably expanded in large quantities in vitro, proliferate faster than mesenchymal stem cells obtained from adult bone marrow or fat, and do not have the tumorigenic potential of embryonic stem cells. Therefore, amniotic fluid stem cells have potential applications in clinical medicine.

[0003] Dry eye disease is commonly known as keratoconjunctivitis sicca. Millions of people suffer from this condition every year, especially with the rapid development of electronic products, which is the most common reason for dry eye disease these days. Dry eye symptoms have traditionally been managed with eyelid hygiene, topical antibiotics, tetracycline, doxycycline, anti-inflammatory compounds (cyclosporine), or corticosteroids, which are often time-consuming, frustrating, and often ineffective or erratic treatments. Summary of the Invention [Problem to be solved by the invention]

[0004] Therefore, there is a need for the development of new therapeutic agents for dry eye disease that can effectively alleviate these symptoms. [Means for solving the problem]

[0005] Summary of the invention In one aspect, the present invention provides a method for treating dry eye disease in a subject comprising administering to the subject a composition comprising a secretome of amniotic fluid stem cells and a pharma- ceutically acceptable carrier; wherein the secretome is prepared by a method comprising the following steps: culturing amniotic fluid stem cells in a basal medium for 24-72 hours to obtain a (conditioned) medium; recovering a culture medium supernatant after centrifugation; and filtering the supernatant to obtain the secretome.

[0006] In one embodiment, the supernatant is filtered through a filter having a pore size of less than 0.5 μm; preferably, the pore size is less than 0.22 μm.

[0007] According to certain embodiments of the invention, the composition is a pharmaceutical composition that is administered topically to the subject's eye, preferably in the form of an eye gel, eye drops, eye wash, eye lotion, eye insert, eye ointment, or eye spray.

[0008] In another aspect, the present invention provides a method for corneal epithelial wound healing in a subject, comprising administering to the subject a composition comprising a therapeutically effective amount of an amniotic fluid stem cell secretome disclosed herein and a pharma- ceutically acceptable carrier.

[0009] In a further aspect, the present invention provides a pharmaceutical composition for use in treating dry eye disease. The pharmaceutical composition comprises a secretome of amniotic fluid stem cells, wherein the secretome is prepared by a method comprising the steps of: culturing amniotic fluid stem cells in a basal medium for 24 to 72 hours to obtain a (conditioned) medium; recovering a culture medium supernatant after centrifugation; and filtering the supernatant to obtain the secretome. The pharmaceutical composition may further comprise a pharma- ceutically acceptable carrier.

[0010] Also provided herein is a pharmaceutical composition for use in corneal epithelial wound healing or treatment of corneal epithelial wounds. The pharmaceutical composition comprises a secretome of amniotic fluid stem cells, wherein the secretome is prepared by a method comprising the steps of: culturing amniotic fluid stem cells in a basal medium for 24-72 hours to obtain a (conditioned) medium; recovering a culture medium supernatant after centrifugation; and filtering the supernatant to obtain the secretome. The pharmaceutical composition may further comprise a pharma- ceutically acceptable carrier.

[0011] In a further aspect, the present invention provides the use of said secretome for the manufacture of a medicament for the treatment of dry eye disease.

[0012] In a further aspect, the present invention provides the use of said secretome for the manufacture of a medicament for corneal epithelial wound healing.

[0013] The present invention is further illustrated by the following examples, however, it should be understood that the following examples are for illustrative purposes only and should not be construed as limiting the disclosure in any way.

[0014] BRIEF DESCRIPTION OF THE DRAWINGS The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. [Brief description of the drawings]

[0015] [Figure 1] FIG. 1 shows a schematic timeline of the experiments in Example 1. [Diagram 2] FIG. 2 shows the tear volume profile collected from each mouse of Example 1 on days 0, 4, and 7 according to FIG. 1 (*p<0.05 compared to the injury group). [Diagram 3] FIG. 3 shows the tear film breakup time (TBUT) profile measured on days 0, 4, and 7 according to FIG. 1 in each mouse eye of Example 1 (*p<0.05 compared to the injury group). [Figure 4]FIG. 4 shows corneal surface photography of mice from Example 1 with ocular UVB injury, including assessment of (A) corneal opacity, (B) corneal smoothness, (C) corneal topography, and (D) Lissamine green staining test; where higher scores indicate more severe injury (*p<0.05 compared to injury group). [Diagram 5] FIG. 5 shows the results of an MTT assay showing the correlation between different concentrations of AFSC (amniotic fluid stem cell) secretome treatment and the viable cell count of human corneal epithelial cells at 24, 48, and 72 hours in Example 2 (*p<0.05 compared to concentration 0). [Figure 6] FIG. 6 shows the results of wound healing assay showing the migration efficiency of human corneal epithelial cells upon treatment of AFSC secretome at 6, 12, 24, and 48 hours (*p<0.05, **p<0.001 compared to concentration 0). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] Description of the Invention The following embodiments are intended to clearly illustrate the above and other technical contents, features and advantages of the present disclosure when read in conjunction with the accompanying drawings. Through the description of the embodiments, those skilled in the art will clearly understand the technical approaches and advantages adopted by the present disclosure to achieve the above aspects.

[0017] Unless otherwise defined, all technical and scientific terms used herein have the same definition as commonly understood by one of ordinary skill in the art to which this disclosure pertains.

[0018] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" or "and" means "and / or" unless specifically stated otherwise. Furthermore, the use of the term "including," as well as other forms such as "include," "includes," "included," etc., is not limiting. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. Unless specifically stated otherwise, all materials used herein are commercially available and readily available.

[0019] As used herein, terms such as "about" refer to a measured amount, such as a dosage, including ±15% or ±10% deviation from the amount specified in one embodiment; ±5% deviation from the amount specified in a preferred embodiment; ±1% deviation from the amount specified in a more preferred embodiment; or ±0.1% deviation from the amount specified in a most preferred embodiment, but the nature of the material to which the amount pertains is unaffected.

[0020] As used herein, the term "disease" means any condition, infection, disorder, or syndrome requiring or for which medical intervention is desirable. Such medical intervention includes treatment, diagnosis, and / or prevention.

[0021] The terms "dry eye disease (DED)", "dry eye syndrome (DES)", "keratoconjunctivitis sicca (KCS)", or simply "dry eye" are used interchangeably to refer to ocular disorders caused by decreased tear production or increased tear film evaporation. Dry eye disease may be the result of another underlying condition that causes dry eye, such as Sjogren's syndrome, menopause, or rheumatoid arthritis. Dry eye may also be a complication of inflammation. Dry eye may be the result of infection, or a side effect of a medication, or exposure to toxins, chemicals, or other substances that may cause dry eye symptoms or conditions. Dry eye disease may be manifested by one or more ophthalmic clinical symptoms as known in the art, including, but not limited to, dryness, foreign body sensation, burning sensation, itching, irritation, redness, eye pain, blurred vision, and / or decreased vision.

[0022] As used herein, the term "secretome," also known as "conditioned medium," refers to the totality (or collection) of proteins that are secreted from a cell into the cell's environment (into the culture medium) when the cell is cultured.

[0023] As used herein, the term "stem cell" refers to undifferentiated cells before they differentiate into individual cells that constitute tissues, and stem cells have the ability to differentiate into specific cells in response to specific differentiation stimuli. According to the present disclosure, the cells used to prepare the secretome of the present disclosure are amniotic fluid stem cells.

[0024] The term "composition" as used herein means a product resulting from the mixing or combination of multiple active ingredients, and includes both fixed and non-fixed combinations of active ingredients. The term "fixed combination" means that both the active ingredient and the specific co-agent are administered to the patient at the same time in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredient and the specific co-agent are administered to the patient as separate entities simultaneously, concurrently, or sequentially without any specific intervening time limit, such administration providing effective levels of the two agents in the patient's body. The latter also applies to cocktail therapy, such as the administration of three or more active ingredients.

[0025] In accordance with the present invention, the term "pharmaceutical composition" as used herein means a therapeutically effective amount of amniotic fluid stem cell secretome or conditioned medium, and optionally a pharma-ceutically acceptable carrier.

[0026] As used herein, the term "pharmaceutical acceptable" means a situation in which, within the scope of reasonable medical judgment, the drug is suitable for use in contact with the tissues of a subject (such as a human) who is to take the drug without undue toxicity, irritation, allergic response, or other problem or complication, and at a reasonable benefit / risk ratio. To be "acceptable," each carrier must be compatible with the other ingredients.

[0027] The term "carrier" as used herein means a non-toxic compound or agent that functions to aid cells or tissues in absorbing the active ingredient. The carrier is selected from, for example, excipients, adjuvants, diluents, fillers or bulking agents, granulating agents, coating agents, release control agents, binders, disintegrants, lubricants, preservatives, surfactants, antioxidants, buffers, suspending agents, thickening agents, stabilizers, or other carriers used in pharmaceutical compositions. Examples of carriers include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropylmethylcellulose, poloxamer, hydroxyethylcellulose cyclodextrin, carboxymethylcellulose (CMC), phosphate buffered saline (PBS), water, emulsifiers (such as oil-water emulsifiers), or wetting agents. Tonicity adjusters may be added as necessary or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or other suitable ophthalmically acceptable tonicity adjusters. Various buffers and means for adjusting the pH can be used as long as the resulting formulation is ophthalmically acceptable. Thus, buffers include acetate, citrate, phosphate and borate buffers. Acids or bases can be used to adjust the pH of these formulations as needed. Similarly, ophthalmically acceptable antioxidants for use in the present disclosure include, but are not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene. Other excipient components that may be included in the ophthalmic formulation are chelating agents and antibiotics. The preferred chelating agent is edetate disodium, although other chelating agents can be used instead or in combination with it.Non-limiting examples of antibiotics useful in the present disclosure include trimethoprim sulfate / polymyxin B sulfate, gatifloxacin, moxifloxacin hydrochloride, tobramycin, teicoplanin, vancomycin, azithromycin, clarithromycin, amoxicillin, penicillin, ampicillin, carbenicillin, ciprofloxacin, levofloxacin, amikacin, gentamicin, kanamycin, neomycin, and streptomycin.

[0028] As used herein, the term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of an administered drug or compound to alleviate to some extent one or more symptoms of the disease or condition being treated. This results in the alleviation and / or mitigation of signs, symptoms, or causes of a disease, or other desired changes in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a peptide or protein disclosed herein that is required to clinically significantly reduce disease symptoms. The appropriate "effective" amount in each individual case can be determined using techniques such as dose escalation studies.

[0029] As used herein, the terms "treat," "treating," or "treatment" refer to the alleviation, relief, or amelioration of at least one symptom of a disease or condition, the prevention of additional symptoms, the inhibition of a disease or condition, e.g., arresting the onset of a disease or condition, relieving a disease or condition, This includes causing the regression of a disease or condition, alleviating the symptoms caused by the disease or condition, or prophylactically and / or therapeutically halting the symptoms of a disease or condition.

[0030] The present invention provides a pharmaceutical composition for treating dry eye disease or corneal epithelial wounds, comprising a secretome of amniotic fluid stem cells, the secretome being prepared by a method comprising the steps of: culturing amniotic fluid stem cells in a basal medium for 24 to 72 hours to obtain a conditioned medium, recovering the culture medium supernatant after centrifugation, and filtering the supernatant to obtain the secretome.

[0031] In one embodiment, the supernatant is filtered through a filter with a pore size of less than 0.5 μm. Preferably, the filter has a pore size of 0.45 μm, 0.3 μm, or 0.22 μm.

[0032] In one embodiment, the composition is a pharmaceutical composition and may further comprise a pharma- ceutically acceptable carrier.

[0033] According to the present invention, a method for treating dry eye disease comprises administering to a subject in need thereof a pharmaceutical composition comprising amniotic fluid stem cell secretome.

[0034] According to the present invention, a method for corneal epithelial wound healing comprises administering to a subject in need thereof a pharmaceutical composition comprising amniotic fluid stem cell secretome.

[0035] The pharmaceutical composition may be administered locally to the eye of a subject, in other words, the pharmaceutical composition may be formulated for topical administration.

[0036] According to certain embodiments of the present invention, the pharmaceutical composition is in the form of an ophthalmic formulation, such as an eye gel, eye drops, eye wash, eye lotion, eye insert, eye ointment, or eye spray.

[0037] The present invention also provides the use of said secretome in the manufacture of a medicament for treating dry eye disease.

[0038] The present invention also provides the use of said secretome in the manufacture of a medicament for corneal epithelial wound healing.

[0039] The present invention is further illustrated by the following examples, which are provided for purposes of illustration and not limitation. EXAMPLES

[0040] Example 1 AFSCs for treatment were obtained by a method including thawing cells from a qualified cell bank such as a Working Cell Bank (WCB) and culturing the cells in MSC NutriStem® XF medium (serum-free / xeno-free). AFSCs were further incubated in basal medium (alpha minimal essential medium) for 48 hours to collect the conditioned medium of AFSCs.

[0041] The conditioned medium collected from the cell culture was then centrifuged at a speed of 2,000 rpm for approximately 10 min and filtered through a 0.22 μm filter to remove cellular debris, after which the secretome of AFSCs was obtained and stored in a −20°C refrigerator for further use.

[0042] Example 2 In this example, an animal model of dry eye was induced by UVB irradiation, and the efficacy of amniotic fluid stem cell secretome in treating dry eye was evaluated based on the experimental results.

[0043] material and method Female ICR albino mice (BioLASCO) were used as the animal model in this example. The experiment started when the mice were 5-6 weeks old. The ICR mice were divided into six groups, each containing six mice (n=6): 1. Healthy control (blank): treated with 0.9% saline by eye drops; 2. Positive control (injury): treated with 0.9% saline via eye drops and treated with UVB to induce injury; 3. Amniotic Fluid Stem Cell Secretome 1 / 5 (1 / 5D): treated with UVB to cause damage and further treated with 1 / 5 dilution of Amniotic Fluid Stem Cell (AFSC) Secretome; 4. Amniotic Fluid Stem Cell Secretome 1 / 5 (1 / 5D): treated with UVB to cause damage and further treated with 1 / 5 dilution of Amniotic Fluid Stem Cell (AFSC) Secretome by eye drops; 5. Amniotic Fluid Stem Cell Secretome 1 / 10 (1 / 10D): treated with UVB to cause damage and further treated with 1 / 10 dilution of Amniotic Fluid Stem Cell (AFSC) Secretome by eye drops; 6. Amniotic Fluid Stem Cell Secretome 1 / 20 (1 / 20D): treated with UVB to cause damage and further treated with 1 / 20 dilution of Amniotic Fluid Stem Cell (AFSC) Secretome by eye drops; 7. Artificial Tears Control (AFT): Treated with 0.9% artificial tears (ALLERGAN) via eye drops and treated with UVB to induce damage.

[0044] Three days before the start of dry eye induction, all mice were administered eye drops twice a day at 10:00 and 17:00 according to a prescribed protocol. UVB irradiation was performed continuously from day 1 to day 7, where the UVB intensity was 0.72 J / cm. 2 It was.

[0045] A schematic timeline of the experiment is shown in Figure 1. Tears were collected on days 0, 4, and 7 to measure changes in tear volume; tear film breakup time (TBUT) was also measured for each mouse on days 0, 4, and 7.

[0046] Mice were sacrificed on day 8 for further histopathological analysis.

[0047] result The tear volume collected from each mouse was measured, and the results are shown in Figure 2. As shown in Figure 2, the effect of tear secretion was improved on the 7th day in the groups treated with AFSC secretome, especially the 1 / 10D treatment group. On the 4th and 7th days, the improvement of the groups treated with AFSC secretome (1 / 5D, 1 / 10D, and 1 / 20D) was statistically significant compared to the positive control (injury) (p<0.05). In contrast, the mice administered artificial tears (AFT) showed significant improvement on the 7th day, but compared to the group treated with AFSC secretome, artificial tears still showed a lower effect in improving tear secretion.

[0048] The tear film break-up time (TBUT) of each mouse was measured, and the results are shown in Figure 3. As shown in Figure 3, the TBUT of each group gradually decreased until day 7, except for the healthy control. However, on days 4 and 7, the TBUT was improved in the groups treated with AFSC secretome (1 / 5D, 1 / 10D, 1 / 20D), which showed statistically significant results compared with the positive control (p<0.05). Although the results did not clearly show a dose-dependent effect, the effect of maintaining the stability of the tear film was higher in the groups treated with AFSC secretome compared with the AFT group.

[0049] Corneal surface photography included assessment of corneal opacity, corneal smoothness, corneal topography, and Lissamine green staining, with higher scores representing greater severity of damage. The photographic results are shown in Figure 4.

[0050] Corneal damage was reduced in all groups treated with AFSC secretome, as shown in Figure 4. Specifically, corneal opacity was reduced in the AFSC secretome-treated group, which also showed statistical significance (p<0.05). Corneal smoothness, topography, and Lissamine green staining also showed improvement with AFSC secretome treatment.

[0051] Furthermore, although AFT was used here as a comparison and also showed improvement, as shown in Figure 4, the improvement with AFT treatment was inferior, therefore, the results suggest that AFSC secretome is a potential alternative to AFT.

[0052] Ocular tissues, including the cornea, lacrimal gland, and meibomian gland (also known as tarsal gland), were subjected to histological and IHC staining.

[0053] H&E staining reveals cell morphology and indicates tissue integrity. IHC targets include Cox-2, p63, PCNA, NFk-B, p53, and 4-HNE. Cox-2 and NFk-B are modulators of immune response and inflammation. p63 and PCNA are modulators of cell proliferation and regeneration. p53 is an apoptotic factor. 4-HNE correlates with oxidative stress.

[0054] Table 1 shows the quantitative results of H&E staining and IHC staining of Cox-2, p63, and PCNA in corneal tissue. (The + mark represents the healthy level.) As shown in Table 1, the treatment of AFSC secretome is effective in alleviating the inflammatory response and promoting cell proliferation after UVB injury in corneal tissue, and the expression of p63 and PCNA increases, but the expression of Cox-2 decreases. The scores of the groups were evaluated as follows: blank > 1 / 10D > 1 / 5D > 1 / 20D > AFT > injury.

[0055] [Table 1]

[0056] Table 2 shows the quantitative results of H&E staining and IHC staining of Cox-2, p53, and NFκ-B in lacrimal gland tissue. As shown in Table 2, the treatment of AFSC secretome was effective in alleviating inflammatory response and inhibiting apoptosis after UVB injury in lacrimal gland tissue, leading to decreased expression of Cox-2, p53, and NFκ-B. The scores of the groups were evaluated as follows: blank > 1 / 10D > 1 / 5D > 1 / 20D > AFT > injury.

[0057] [Table 2]

[0058] Table 3 shows the quantitative results of H&E staining and IHC staining of Cox-2, 4-HNE, and NFκ-B in meibomian gland tissue. As shown in Table 3, the treatment of AFSC secretome was effective in alleviating inflammatory response and reducing oxidative stress after UVB injury in lacrimal gland tissue, leading to decreased expression of Cox-2, 4-HNE, and NFκ-B. The scores of the groups were evaluated as follows: blank > 1 / 10D > 1 / 5D > 1 / 20D > AFT > injury.

[0059] [Table 3]

[0060] Considering Tables 1 to 3, treatment of AFSC secretome can maintain cell tissue integrity, alleviate inflammation, rescue cells from apoptosis, and promote proliferation after UVB injury, suggesting that AFSC secretome is a potent agent to repair and restore ocular tissues such as the cornea.

[0061] Example 3 In this example, human corneal epithelial cells were treated with AFSC secretome and the effect was observed.

[0062] material and method The method for obtaining conditioned medium of AFSCs was the same as in Example 1 and will not be repeated here.

[0063] Human corneal epithelial cells (HCECs) (Thermo Fisher) were incubated in keratinocyte serum-free medium (SFM) (Thermo Fisher) at 37°C and 5% CO2.

[0064] To obtain a cell suspension, the medium was discarded and the cells were washed with 3 ml of DPBS (Dulbecco's phosphate buffered saline). After discarding the DPBS, 1 ml of 0.05% trypsin was added and the cells were left at 37°C for 5 to 7 minutes.

[0065] After confirming under a microscope that the cells had rounded up and detached, the cells were suspended in 2 ml of medium to weaken the reaction of trypsin.

[0066] 20 μl of the suspension was taken, and the same amount of trypan blue was added and mixed with the suspension, after which 10 μl of the mixture was taken and the number of cells was counted using a cytometer.

[0067] To evaluate the effect of AFSC secretome on corneal cells, we performed the MTT assay. The MTT assay is a colorimetric assay for evaluating the metabolic activity and viability of cells. NAD(P)H-dependent cellular oxidoreductases can reflect the number of viable cells present under defined conditions. These enzymes can reduce the tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to a purple insoluble formazan.

[0068] HCECs were plated in 96-well plates with 8,000 cells per well. 100 μl of culture medium was added and cells were incubated for 24 hours. After that, cells were treated with 100 μl of AFSC secretome solution at different concentrations (1 / 2, 1 / 8, and 1 / 32 dilutions) and continued incubation for 24, 48, and 72 hours, respectively.

[0069] When the incubation was completed according to the above time, the medium was replaced with 200 μl of MTT solution, the plate was discarded and reacted for 3 hours. Furthermore, the MTT solution was replaced with DMSO to dissolve the crystals. The cells were analyzed by an ELISA reader to detect the absorbance below 570 nm.

[0070] Meanwhile, wound healing assay was performed. 5The cells were incubated in 12-well plates containing 1 ml of medium in each well for 24 hours. At the end of the incubation, a 200 μl pipette tip was used to draw three lines on the bottom of the well. The medium was then discarded, the cells were washed with DPBS, and 500 μl of medium was added. The plates were observed and photographed under a 100x microscope to record the starting state of cell migration (0 hours).

[0071] Then, 500 μl of AFSC secretome solution at different concentrations (1 / 2, 1 / 8, and 1 / 32 dilutions) was added. Furthermore, the plates were observed and photographed 6, 12, 24, and 48 hours after the initiation of cell migration. The migration distance was calculated according to the following formula: Distance=[(D0-Dn) / D0]x100% [Where D0 is the scratch width at 0 hours, Dn is the scratch width after 6, 12, 24 and 48 hours.]

[0072] All experimental results were expressed as mean ± SD (standard deviation). Statistics for homogeneity were performed by one-way analysis of variance, and significance at each time point was determined by Scheffe's post hoc test. P<0.05 indicates statistical significance; p<0.001 indicates high statistical significance.

[0073] result The results of the MTT assay showing the effect of AFSC secretome on human corneal cells are shown in Figure 5, which shows the correlation between the treatment of different concentrations of AFSC secretome and cell viability at 24, 48, and 72 hours.

[0074] As shown in Figure 5, the OD570 absorbance (cell viability) increased with the level of AFSC secretome. The efficiency of improving viability also increased with the level of AFSC secretome. Among all groups, the group treated with 1 / 2 dilution of AFSC secretome showed the most significant improvement.

[0075] The results of the wound healing assay showing the effect of AFSC secretome on corneal cell migration are shown in Figure 6, which shows the efficiency of migration by AFSC secretome treatment at 6, 12, 24, and 48 hours.

[0076] As shown in Figure 6, the group treated without AFSC secretome (negative control) showed only slight migration from 0 to 48 hours, which was not significant. In contrast, the AFSC secretome-treated group showed significant migration from 24 to 48 hours. Furthermore, the groups treated with 1 / 2 and 1 / 8 dilutions of AFSC secretome showed nearly 100% migration at 48 hours, indicating a nearly complete recovery of the scratch width, and the group treated with 1 / 32 dilution of AFSC secretome showed approximately 80% migration.

[0077] Considering the results of this example, the secretome of AFSCs could not only improve the survival and viability of human corneal cells but also enhance the migration efficiency of human corneal cells, thus indicating the therapeutic potential of the secretome of AFSCs as a treatment for dry eye.

Claims

1. A pharmaceutical composition for use in the treatment of dry eye disease, comprising a secretome of amniotic fluid stem cells, wherein the secretome is prepared by a method comprising the steps of: culturing amniotic fluid stem cells in a basal medium for 48 to 72 hours to obtain a culture medium; recovering a supernatant of the culture medium after centrifugation; and filtering the supernatant to obtain the secretome, wherein the supernatant is filtered through a filter having a pore size of 0.22 μm to less than 0.5 μm.

2. 2. The pharmaceutical composition for use according to claim 1, which is administered topically.

3. 3. The pharmaceutical composition for use according to claim 2, in the form of an eye gel, eye drops, eye wash, eye lotion, eye insert, eye ointment, or eye spray.

4. A pharmaceutical composition for use in corneal epithelial wound healing, comprising a secretome of amniotic fluid stem cells, wherein the secretome is prepared by a method comprising the steps of: culturing amniotic fluid stem cells in a basal medium for 48 to 72 hours to obtain a culture medium; recovering a supernatant of the culture medium after centrifugation; and filtering the supernatant to obtain the secretome, wherein the supernatant is filtered through a filter having a pore size of 0.22 μm to less than 0.5 μm.

5. 5. The pharmaceutical composition for use according to claim 4, which is administered topically.

6. 6. The pharmaceutical composition for use according to claim 5, in the form of an eye gel, eye drops, eye wash, eye lotion, eye insert, eye ointment, or eye spray.

Citation Information

Patent Citations

  • Use of Amniotic Fluid (Af) in Treating Ocular Disease and Injury

    US20080286378A1

  • Amniotic fluid topical formulation

    US20170100440A1